156 related articles for article (PubMed ID: 11102735)
1. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
de Lange EC; Marchand S; van den Berg D; van der Sandt IC; de Boer AG; Delon A; Bouquet S; Couet W
Eur J Pharm Sci; 2000 Dec; 12(2):85-93. PubMed ID: 11102735
[TBL] [Abstract][Full Text] [Related]
2. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
3. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123.
de Lange EC; de Bock G; Schinkel AH; de Boer AG; Breimer DD
Pharm Res; 1998 Nov; 15(11):1657-65. PubMed ID: 9833984
[TBL] [Abstract][Full Text] [Related]
4. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
J Pharm Pharmacol; 2001 May; 53(5):699-709. PubMed ID: 11370709
[TBL] [Abstract][Full Text] [Related]
5. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
6. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.
van der Sandt IC; Smolders R; Nabulsi L; Zuideveld KP; de Boer AG; Breimer DD
Eur J Pharm Sci; 2001 Aug; 14(1):81-6. PubMed ID: 11457654
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation.
Ooie T; Suzuki H; Terasaki T; Sugiyama Y
Pharm Res; 1996 Jul; 13(7):1065-8. PubMed ID: 8842046
[TBL] [Abstract][Full Text] [Related]
9. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
10. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
12. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Teft WA; Mansell SE; Kim RB
Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
[TBL] [Abstract][Full Text] [Related]
13. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
14. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
[TBL] [Abstract][Full Text] [Related]
16. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.
Davey PG; Charter M; Kelly S; Varma TR; Jacobson I; Freeman A; Precious E; Lambert J
Antimicrob Agents Chemother; 1994 Jun; 38(6):1356-62. PubMed ID: 8092837
[TBL] [Abstract][Full Text] [Related]
18. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.
Xie R; Hammarlund-Udenaes M; de Boer AG; de Lange EC
Br J Pharmacol; 1999 Oct; 128(3):563-8. PubMed ID: 10516633
[TBL] [Abstract][Full Text] [Related]
19. Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain.
Hong L; Xu C; O'Neal S; Bi HC; Huang M; Zheng W; Zeng S
Acta Pharmacol Sin; 2014 Dec; 35(12):1577-85. PubMed ID: 25418377
[TBL] [Abstract][Full Text] [Related]
20. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
